Genaera Corporation has commenced its multi-center, open-label, pharmacodynamic Phase II clinical trial, MSI-1256F-212 ("Study 212") that will evaluate the efficacy and safety of EVIZON™ (squalamine lactate) at higher doses.
EVIZON™ (squalamine lactate) is Genaera's lead product under development indicated for ophthalmic conditions, specifically wet age-related macular degeneration (AMD).
This study will provide more detailed information on EVIZON's effects on visual acuity in both affected eyes of patients with exudative AMD. There is a significant medical need for a drug that treats wet AMD in both eyes simultaneously, while avoiding the complications of intravitreal injections.
For those who might be interested in participating in EVIZON™ clinical trials, patients and physicians may call Genaera's Clinical Trial Hotline at (800) 299-9156.
More detailed information at Genaera’s press release (a pdf file).
Comment Preview